Abstract
Background and aim: There is a considerable heterogeneity in metabolic phenotype among equally obese subjects. Impaired GH secretion is frequent in obese patients, with GH secretion reduced up to levels that are comparable to those found in adult patients with organic GH deficiency (GHD). Low GH status exerts detrimental effects on metabolic abnormalities in organic GHD patients. The aim of this observational, retrospective study was to investigate the prevalence of the metabolic syndrome (MetS) in moderately-severely obese subjects who met criteria for GDH (GHD) and in those with normal GH status (GH sufficient: GHS). Methods and results: One-hundred and ninety-five moderately-severely obese individuals partecipated, 149 women and 46 males [body mass index (BMI) 43.0±4.4 kg/m2 aged 34.3±11.8 yr]. Main outcome measures were: GH peak after GHRH plus arginine test, IGF-I, MetS parameters according to National Cholesterol Education Program criteria. Fifty-five subjects (27.3%) were GHD (49 females and 6 males). The prevalence of MetS parameters was 70.9% in GHD subgroup vs 52.9% in GHS (χ2=5.281; p=0.02) and the likelihood of MetS was highest in GHD subgroup (odds ratio: 2.174; 95% confidence interval 1.113 to 4.248). At the multiple regression analysis either GH peak or IGF-I were the major determinants of waist circumference (β=-0.380, t=−6.110 and β=-0.326, t=−4.704, respectively; p<0.001), while age and IGF-I were the major determinants of MetS (β=0.255, t= 3.342, and β=−0.282, t=−3.270; p=0.02, respectively). Conclusions: Among moderately-severely obese individuals the prevalence of the MetS was higher in GHD than in GHS subjects. Thus, in obese subjects, GH status investigation might be considered in the clinical evaluation of their metabolic risk profile.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000, 6: 697–738.
Sims EA. Are there person who are obese, but metabolically healthy? Metabolism 2001, 50: 1499–504.
Guy-Grand B. From obesity to obesities: from concepts to practicies. Ann Endocrinol (Paris) 2003, 64: S7–15.
Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 2008, 168: 1617–24.
Després JP, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28: 1039–49.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287: 356–9.
Bonora E, Kiechl S, Willeit J, et al; Bruneck Study. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003, 27: 1283–9.
Bonora E. The metabolic syndrome: Is it still alive? In: G. Crepaldi, A. Tiengo, A. Avogaro eds. The metabolic syndrome: The road map from inflammation to cardiovascular disease. ICS1303. Amsterdam: Elsevier B.V. 2007, 2–9.
Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health 2001, 22: 355–75.
Kopelman P. Health risks associated to overweight and obesity. Obes Rev 2007, 8: 13–7.
Björntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord 2000, 24: S80–5.
Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am 2003, 32: 895–914.
Björntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996, 20: 291–302.
Maccario M, Grottoli S, Procopio M, et al. The GH/IGF-I axis in obesity: influences of neuroendocrine and metabolic factors. Int J Obes Relat Disord 2000, 24: S96–9.
Burt MG, Gibney J, Ho KK. Characterization of the metabolic phenotypes of Cushing’s syndrome and growth hormone deficiency: a study of body composition and energy metabolism. Clin Endocrinol (Oxf) 2006, 64: 436–43.
Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991, 72: 51–9.
Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999, 23: 260–71.
Franco C, Bengtsson BA, Johannsson G. Visceral obesity and the role of the somatotropic axis in the development of metabolic complications. Growth Horm IGF Res 2001, 11: S97–102.
Pasquali R, Vicennati V, Gambineri A, Pagotto U. Hormones and pathophysiology of obesity. Eat Weight Disord 2001, 6 (3 Suppl): 9–20.
Savastano S, Di Somma C, Mentone A, et al. GH insufficiency in obese patients. J Endocrinol Invest 2006, 29: 42–53.
Corneli G, Di Somma C, Baldelli R, et al. The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol 2005, 153: 257–64.
Tanaka K, Inoue S, Numata K, Okazaki H, Nakamura S, Takamura Y. Very-low calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Metabolism 1990, 39: 892–6.
Rasmussen MH, Hvidberg A, Juul A, et al. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995, 80: 1407–15.
Maccario M, Valetto MR, Savio P, et al. Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. Int J Obes Relat Metab Disord 1997, 21: 27–32.
Umpleby AM, Russel-Jones DL. The hormonal control of protein metabolism. Baillieres Clin Endocrinol Metab 1996, 10: 551–70.
Møller N, Gjedsted J, Gormsen L, Fuglsang J, Djurhuus C. Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res 2003, 13: S18–21.
Colao A, Di Somma C, Savanelli MC, De Leo M, Lombardi G. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006, 16: S41–8.
Ho KK; GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol 2007, 157: 695–700.
Bengtsson BA, Johannsson G, Shalet SM, Simpson H, Sonken PH. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000, 85: 933–42.
Colao A, Di Somma C, Cuocolo A, et al. The severity of growth hormone deficiency correlates with the severity of cardiac impairment in 100 adult patients with hypopituitarism: an observational, case-control study. J Clin Endocrinol Metab 2004, 89: 5998–6004.
Beauregard C, Utz A, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008, 93: 2063–71.
Albert SG, Mooradian AD. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity. J Clin Endocrinol Metab 2004, 2: 695–701.
Johannsson G, Mårin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997, 82: 727–34.
Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab 2005, 90: 1466–74.
Savastano S, Di Somma C, Belfiore A, et al. Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest 2006, 29: 536–43.
Lamberts SW, de Herder WW, van der Lely AJ. Pituitary insufficiency. Lancet 1998, 352: 127–34.
Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735–52.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20: 1183–97.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.
Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996, 134: 352–6.
Colao A, Di Somma C, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008, 159: 389–97.
Corneli G, Di Somma C, Baldelli R, Rovere S, Gasco V, Croce CG. The cut-off limits of the GH response to GH-releasing hormonearginine test related to body mass index. Eur J Endocrinol 2005, 153: 257–64.
Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults — a KIMS database analysis. Eur J Endocrinol 2006, 155: 79–90.
Johannsson G, Bengtsson BA. Growth hormone and the metabolic syndrome. J Endocrinol Invest 1999, 22 (5 Suppl): 41–6.
Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008, 168: 1609–16.
Wolf AM, Buffington C, Beisiegel U. Comparison of metabolic risk factors between severely and very severely obese patients. Obesity (Silver Spring) 2006, 14: 2177–83.
Girod JP, Brotman DJ. The metabolic syndrome as a vicious cycle: does obesity beget obesity? Med Hypotheses 2003, 60: 584–9.
Drapeau V, Lemieux I, Richard D, et al. Metabolic profile in severely obese women is less deteriorated than expected when compared to moderately obese women. Obes Surg 2006, 16: 501–9.
Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation 2004, 109: 706–13.
Pasquali R, Vicennati V, Cacciari M, Pagotto U. The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci 2006, 1083: 111–28.
Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab 2008, 93: 2507–14.
Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106: 939–44.
Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy population independently of age. J Endocrinol Invest 2005, 28: 440–8.
Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentration of insulin-like growth factor I and development of glucose intolerance: a prospective observational study. Lancet 2002, 359: 1740–5.
Maison P, Balkau B, Souberbielle JC, et al; D. E. S. I. R. Study Group. Evidence for distinct effects of GH and IGF-I in the metabolic syndrome. Diabet Med 2007, 24: 1012–8.
Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 2007, 30: 2145–7.
Makimura H, Stanley T, Mun D, You SM, Grinspoon S. The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men. J Clin Endocrinol Metab 2008, 93: 4254–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Di Somma, C., Pivonello, R., Pizza, G. et al. Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 33, 171–177 (2010). https://doi.org/10.1007/BF03346577
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346577